Experts offer their thoughts on what the specialty pharmacy industry will look like over the next year.
Earlier this year, HHS announced a new proposed rule concerning drug rebates. This rule, which proposes to eliminate safe harbor protections for rebates paid by drug manufacturers to PBMs, Medicare Part D plans, and Medicaid managed care plans, has many wondering what the effects may be on the specialty pharmacy, said Adam J. Fein, Ph.D., chief executive officer of the Drug Channels Institute. Many analysts have suggested that the implementation of such a rule would significantly disrupt the way the drug supply chain currently operates.
“Two years ago, did you think we would ever be talking about moving to a world without rebates?” Fein asked the attendees at his 2019 Asembia Specialty Pharmacy, in a panel he co-presented with Lisa Gill, a healthcare equity research analyst at J.P. Morgan, and Doug Long, vice president of Industry Relations at IQVIA.
In the presentation, entitled, “Specialty Pharmacy Industry Outlook: What’s Next?”, Fein used his time to discuss what he believes such a rule-and the resulting “crazy, out-of-control scenario”-might mean for the specialty pharmacy industry.
“Number one, the entire way that plans and PBMs manage specialty spending will have to change,” he said. Today, he said, plans and PBMs factor in rebates in their decision-making-and the proposed rule could affect the ability of new specialty drugs to launch as well patient access to those drugs. As a result, he believes we will see brand name drugs banishing generic equivalents as well as much narrower formularies. And in specialty categories, he said, drugs launching with new indications would be able to do so with visibly lower net prices.
“Three or four years down the road, the whole economic model of specialty pharmacy, and specialty distribution, will need to be rethought,” he said. “Now, everyone is basing their model on list price. You’re basing your revenue, your cost of goods on list price. But if that price is 20, 30, 50, or 60% lower than it is now, approximating the true net cost, the margins in this business simply would not work. This rule would not make just a little difference. This would be an explosion.”
Related article: How Mergers Change Specialty Pharmacy
Gill and Long agreed that the future is uncertain. Gill discussed how so many plans use those rebate dollars to help fund important side programs like behavioral health or member incentive programs-and will have to rethink how to find the dollars to make them happen. And that is making Wall Street a bit nervous. But that said, most PBMs are now part of larger companies and have some support to weather future storms.
“How plans make their money is what will really change with this rule,” she said. “Their ability to put clinical programs in place and drive programs that make sense of patients will change. But I think those programs are still going to be there. I also think that PBMs will continue to grow.”
Long added that Wall Street “hates PBMs because they don’t understand them.” He said that PBMs add value by providing intermediary relationships between pharmaceutical companies and health plans. But part of the challenge is that their services often appear free to plan sponsors because compensation spreads, including rebates, are so opaque.
“The market, in the past, has allowed [PBMs] to operate in this way,” he said. “Plan sponsors haven’t disciplined the PBMs, which, to some extent, is really their job. So, if plan sponsors don’t like what’s going on, they should do something about it.”
The big question, moving forward, is how companies will “discipline” PBMs if rebates disappear-and whether insurance companies can “unbundle” drug costs in order to get a clear understanding of their net costs. But, despite so much uncertainty, Fein, and his fellow panel members, remained optimistic that specialty pharmacy, as an industry, will find a successful path forward.
“This is a very dynamic time-prime time for greater change than I have ever seen in this century,” Fein said. “My final piece of advice to you, with all this change, with all this trouble, and with all this complexity, is to try to stay positive but, as always, test negative.”
Kayt Sukel is a science and health writer based outside Houston.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More